AlphaCrest Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

AlphaCrest Capital Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,021	Closed	-$320K	–	1428
2022 Q2	$320K	Buy	+10,021	New	+$293K	0.02%	1098
2022 Q1	–	Sell	-9,131	Closed	-$267K	–	1460
2021 Q4	$267K	Sell	9,131 -7,914	-46%	-$245K	0.01%	1284
2021 Q3	$434K	Sell	17,045 -7,963	-32%	-$234K	0.02%	973
2021 Q2	$876K	Buy	+25,008	New	+$976K	0.04%	728
2020 Q3	–	Sell	-4,400	Closed	-$278K	–	1221
2020 Q2	$278K	Sell	4,400 -3,100	-41%	-$213K	0.05%	668
2020 Q1	$383K	Buy	+7,500	New	+$502K	0.05%	692
2019 Q4	–	Sell	-5,700	Closed	-$277K	–	1425
2019 Q3	$277K	Buy	+5,700	New	+$297K	0.02%	1120

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AlphaCrest Capital Management's GBT Position: Q3 2022 in Review

AlphaCrest Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 10,021 shares — an estimated $320K sold.

AlphaCrest Capital Management first reported a position in GBT in Q3 2019 and held it in 7 quarters. The position peaked at $876K in Q2 2021. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

AlphaCrest Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 10,021 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $320K.
AlphaCrest Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q3 2019 and held it in 7 quarters.
AlphaCrest Capital Management's Global Blood Therapeutics, Inc. position peaked at $876K in Q2 2021.
247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on AlphaCrest Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.